Moneycontrol PRO
you are here: HomeNewsBusiness

COVID-19 pandemic | Wipro hired 7,000 in Q1 FY21, will continue to hire in coming quarters

Fresher on-boarding that started in Q2 will continue in the phased manner through Q3.

July 15, 2020 / 08:16 PM IST

India’s fourth largest IT major Wipro hired 7,000 people globally for the quarter-ending June. Hiring will continue in coming quarters depending on demand, said Saurabh Govil, its Chief Human Resources Officer.

Speaking to mediapersons during its recent Q1 FY21 earnings announcement, Govil, said, “Lateral hiring never stopped. Growth is the agenda and we will continue to hire in Q2 and onwards.”

However, he was quick to add that hiring would depend on the need basis.

The company has started on-boarding freshers with earlier offers in a phased manner. “It would be staggered and delayed based on business requirements,” he added. The on-boarding, Govil said, will happen right from July to September till December.

The deferral was on account of delays in terms of closing of the curriculum and academic session.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

During the March quarter result, the company said it will go slow on hiring on the back of COVID-19. The company had doubled its hiring in FY20.

According to reports, the company had hired 12,000 freshers last fiscal and was planning to hire similar numbers in FY21. While Govil said lateral hiring will continue, he did not discloses any numbers for campus hiring.

Total employee count stood at 1,81,804 for the quarter-ended June, down 1,000 from the preceding quarter. Utilisation levels stood at 75 percent, up from 73.4 percent in Q4 FY20.

Where is the company seeing traction?

Technology adaption is one of the huge driving factors on the back of pandemic. Jatin Dalal, its Chief Financial Officer, said areas that saw huge opportunities during COVID-19 include cloud, remote working solutions, and cybersecurity.

The company also made a recent acquisition, IVIA, in Brazil, which Dalal said will help the company set up delivery centres in the northeast of Brazil. IVIA is a IT solutions service provider with 750 employees.

Moneycontrol News
first published: Jul 14, 2020 10:21 pm